company background image
BCARTB logo

Biocartis Group BATS-CHIXE:BCARTB Stock Report

Last Price

€1.71

Market Cap

€68.3m

7D

0%

1Y

n/a

Updated

30 Oct, 2022

Data

Company Financials +

Biocartis Group NV

BATS-CHIXE:BCARTB Stock Report

Market Cap: €68.3m

BCARTB Stock Overview

A molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. More details

BCARTB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Rewards

Revenue is forecast to grow 34.34% per year

Risk Analysis

Earnings have declined by 10.5% per year over past 5 years

Negative shareholders equity

Shares are highly illiquid

Has less than 1 year of cash runway

+ 1 more risk

Biocartis Group NV Competitors

Creo Medical Group

AIM:CREO

UK£66.9m

ANGLE

AIM:AGL

UK£33.9m

Ondine Biomedical

AIM:OBI

UK£22.9m

Polarean Imaging

AIM:POLX

UK£18.7m

Price History & Performance

Summary of all time highs, changes and price drops for Biocartis Group
Historical stock prices
Current Share Price€1.71
52 Week High€3.62
52 Week Low€1.71
Beta1.7
11 Month Change0%
3 Month Changen/a
1 Year Changen/a
33 Year Change-73.01%
5 Year Change-86.40%
Change since IPO-74.23%

Recent News & Updates

Recent updates

Shareholder Returns

BCARTBGB Medical EquipmentGB Market
7D0%-0.2%1.7%
1Yn/a-2.3%8.3%

Return vs Industry: Insufficient data to determine how BCARTB performed against the UK Medical Equipment industry.

Return vs Market: Insufficient data to determine how BCARTB performed against the UK Market.

Price Volatility

Is BCARTB's price volatile compared to industry and market?
BCARTB volatility
BCARTB Average Weekly Movementn/a
Medical Equipment Industry Average Movement6.3%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.3%
10% least volatile stocks in GB Market2.6%

Stable Share Price: BCARTB has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine BCARTB's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007619Herman Verrelstwww.biocartisgroupnv.be

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test.

Biocartis Group NV Fundamentals Summary

How do Biocartis Group's earnings and revenue compare to its market cap?
BCARTB fundamental statistics
Market cap€68.35m
Earnings (TTM)-€62.96m
Revenue (TTM)€58.61m

1.2x

P/S Ratio

-1.1x

P/E Ratio

Is BCARTB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BCARTB income statement (TTM)
Revenue€58.61m
Cost of Revenue€73.13m
Gross Profit-€14.52m
Other Expenses€48.45m
Earnings-€62.96m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 10, 2022

Earnings per share (EPS)-1.08
Gross Margin-24.77%
Net Profit Margin-107.42%
Debt/Equity Ratio-209.9%

How did BCARTB perform over the long term?

See historical performance and comparison